Patents by Inventor Peter Turecek

Peter Turecek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins
    Patent number: 9265791
    Abstract: Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: February 23, 2016
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Peter Turecek, Susanne Vejda
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20160033506
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: November 20, 2014
    Publication date: February 4, 2016
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor
    Patent number: 9110085
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 18, 2015
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • RECOMBINANT VWF FORMULATIONS
    Publication number: 20150216983
    Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 6, 2015
    Inventors: Peter Matthiessen, Peter Turecek, Hans-Peter Schwarz, Kurt Schnecker
  • Method for the validatable inactivation of pathogens in a biological fluid by irradiation
    Patent number: 8986607
    Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Materials and methods for conjugating a water soluble fatty acid derivative to a protein
    Patent number: 8945897
    Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Richard Sheinecker, Hanspeter Rottensteiner, Peter Turecek
  • NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE
    Publication number: 20150024455
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 22, 2015
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20140335071
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 13, 2014
    Applicant: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Method for preparing FMOC-based hydrolysable linkers
    Patent number: 8871949
    Abstract: A novel process for the production of Fmoc (9H-fluoren-9-ylmethoxycarbonyl)-based compounds is provided, wherein a protecting group for the 9-hydroxymethyl group of the fluorene ring system is utilized. These compounds are useful for the modification of protein and peptide drugs.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Juergen Siekmann, Christian Noe, Gerhard Stoiber
  • ETHANOL DEPENDENCE OF ALPHA1 ANTITRYPSIN C-TERMINAL LYS TRUNCATION BY BASIC CARBOXYPEPTIDASES
    Publication number: 20140309176
    Abstract: The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.
    Type: Application
    Filed: May 27, 2014
    Publication date: October 16, 2014
    Inventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
    Patent number: 8846620
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: September 30, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Susanne Vejda
  • RESORPTION ENHANCERS AS ADDITIVES TO IMPROVE THE ORAL FORMULATION OF LOW MOLECULAR WEIGHT HEPARINS
    Publication number: 20140271608
    Abstract: Aspects of the invention include methods for treating or preventing a thromboembolic disease in a subject. In practicing methods according to certain embodiments, an amount of a low molecular weight heparin (LMWH) and a synergistically effective combination of two or more gastrointestinal epithelial barrier permeation enhancers is orally administered to a subject in a manner sufficient to treat the thromboembolic disease in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Application
    Filed: January 21, 2014
    Publication date: September 18, 2014
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Susanne Vejda
  • Polymer von Willebrand factor-conjugates
    Patent number: 8835388
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 16, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Peter Turecek, Jueren Siekmann
  • Methods for differentiating plasma-derived protein from recombinant protein in a sample
    Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A PATIENT'S BLOOD OR PLASMA
    Publication number: 20140232029
    Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicants: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Peter Turecek, Brigitte Keil, Sylvia Peyrer-Heimstaett, Hans-Peter Schwarz
  • Nucleophilic catalysts for oxime linkage
    Patent number: 8809501
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 19, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Ethanol dependence of alpha1 antitrypsin C-terminal lys truncation by basic carboxypeptidases
    Patent number: 8772240
    Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: July 8, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
    Publication number: 20140186323
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20140154709
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: November 12, 2013
    Publication date: June 5, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONSL INC.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
    Patent number: 8735086
    Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: May 27, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Peter Turecek, Brigitte Keil, Sylvia Peyrer-Heimstaett, Hans-Peter Schwarz